See more : DoorDash, Inc. (DASH) Income Statement Analysis – Financial Results
Complete financial analysis of PROCEPT BioRobotics Corporation (PRCT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PROCEPT BioRobotics Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Sleepz AG (SLZ.WA) Income Statement Analysis – Financial Results
- MAAS Group Holdings Limited (MGH.AX) Income Statement Analysis – Financial Results
- FieldPoint Petroleum Corporation (FPPP) Income Statement Analysis – Financial Results
- Advanced Technology & Materials Co., Ltd. (000969.SZ) Income Statement Analysis – Financial Results
- Royal Wins Corporation (SKLL.CN) Income Statement Analysis – Financial Results
PROCEPT BioRobotics Corporation (PRCT)
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 136.19M | 75.01M | 34.47M | 7.72M | 6.17M |
| Cost of Revenue | 65.14M | 37.93M | 18.61M | 8.97M | 8.05M |
| Gross Profit | 71.05M | 37.09M | 15.87M | -1.26M | -1.89M |
| Gross Profit Ratio | 52.17% | 49.44% | 46.02% | -16.26% | -30.56% |
| Research & Development | 48.45M | 28.98M | 18.99M | 16.28M | 13.15M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 131.77M | 88.83M | 51.04M | 30.27M | 28.52M |
| Other Expenses | 0.00 | -203.00K | -154.00K | -25.00K | -46.00K |
| Operating Expenses | 180.22M | 117.81M | 70.03M | 46.55M | 41.67M |
| Cost & Expenses | 245.36M | 155.74M | 88.64M | 55.52M | 49.72M |
| Interest Income | 7.55M | 2.01M | 121.00K | 184.00K | 1.15M |
| Interest Expense | 4.00M | 5.18M | 5.81M | 5.26M | 724.00K |
| Depreciation & Amortization | 3.81M | 4.32M | 2.98M | 2.70M | 1.49M |
| EBITDA | -98.10M | -77.65M | -51.06M | -45.06M | -39.76M |
| EBITDA Ratio | -72.03% | -104.93% | -156.77% | -580.32% | -663.85% |
| Operating Income | -109.17M | -80.72M | -54.16M | -47.80M | -43.55M |
| Operating Income Ratio | -80.16% | -107.61% | -157.12% | -619.44% | -705.95% |
| Total Other Income/Expenses | 3.27M | -6.43M | -5.69M | -5.22M | 1.58M |
| Income Before Tax | -105.90M | -87.15M | -59.85M | -53.02M | -41.98M |
| Income Before Tax Ratio | -77.76% | -116.18% | -173.62% | -687.04% | -680.42% |
| Income Tax Expense | 0.00 | 6.43M | 2.53M | 5.24M | 678.00K |
| Net Income | -105.90M | -93.58M | -62.38M | -58.26M | -42.65M |
| Net Income Ratio | -77.76% | -124.76% | -180.96% | -754.89% | -691.41% |
| EPS | -2.24 | -2.11 | -1.43 | -1.35 | -0.99 |
| EPS Diluted | -2.24 | -2.11 | -1.43 | -1.35 | -0.99 |
| Weighted Avg Shares Out | 47.26M | 44.40M | 43.68M | 43.25M | 43.25M |
| Weighted Avg Shares Out (Dil) | 47.26M | 44.40M | 43.68M | 43.25M | 43.25M |
Procept BioRobotics Has Resources To Ramp Up Commercialization
Procept BioRobotics went public in September 2021, raising approximately $164 million in an IPO. The firm is commercializing a water-based ablation device to treat benign prostatic hyperplasia, a common condition in older men.
PROCEPT BioRobotics Corp. to Present at 2022 Wells Fargo Healthcare Conference
REDWOOD CITY, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present and host a...
PROCEPT BioRobotics Corporation's (PRCT) CEO Reza Zadno on Q2 2022 Results - Earnings Call Transcript
PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Matt Bacso - Investor Relations Reza Zadno - Chief Executive Officer Kevin Waters - Chief Financial Officer Conference Call Participants Joshua Jennings...
PROCEPT BioRobotics to Report Second Quarter 2022 Financial Results on August 4, 2022
REDWOOD CITY, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter...
Procept: Leveraging A Novel Water-Based System For Enlarged Prostate Treatment
PROCEPT has developed a system to treat enlarged prostate disease, and is banking on competitive advantage over legacy treatment options. The common disease, more prevalent as populations grow older, provides the company with a large TAM to drive growth.
PROCEPT BioRobotics Corporation (PRCT) CEO Reza Zadno on Q1 2022 Results - Earnings Call Transcript
PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Matt Bacso - Investor Relations Reza Zadno - Chief Executive Officer Kevin Waters - Chief Financial Officer Conference Call Participants Josh Jennings...
PROCEPT BioRobotics Corp. to Report First Quarter 2022 Financial Results on May 5, 2022 and attend the 2022 Bank of America Healthcare Conference on May 11, 2022
REDWOOD CITY, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the first quarter...
Andreas Halvorsen Powers Down Position in PROCEPT BioRobotics
Viking Global leader Andreas Halvorsen (Trades, Portfolio) disclosed earlier this week he curbed his PROCEPT BioRobotics Corp. ( PRCT , Financial) stake by 25.45%.
PROCEPT BioRobotics (PRCT) CEO Reza Zadno on Q4 2021 Results - Earnings Call Transcript
PROCEPT BioRobotics (PRCT) CEO Reza Zadno on Q4 2021 Results - Earnings Call Transcript
6 Underperforming IPO Stocks To Buy On The Dip
The U.S. IPO market was red-hot in 2021. The total number of traditional U.S. IPOs hit its highest level since the dot-com boom in the late 1990s, while total IPO deal value reached record levels last year.
Source: https://incomestatements.info
Category: Stock Reports